GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silverback Therapeutics Inc (NAS:SBTX) » Definitions » Inventories, Inventories Adjustments

Silverback Therapeutics (Silverback Therapeutics) Inventories, Inventories Adjustments : $0.00 Mil (As of Sep. 2022)


View and export this data going back to 2020. Start your Free Trial

What is Silverback Therapeutics Inventories, Inventories Adjustments?

Silverback Therapeutics's Inventories, Inventories Adjustments for the quarter that ended in Sep. 2022 was $0.00 Mil.


Silverback Therapeutics Inventories, Inventories Adjustments Historical Data

The historical data trend for Silverback Therapeutics's Inventories, Inventories Adjustments can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silverback Therapeutics Inventories, Inventories Adjustments Chart

Silverback Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21
Inventories, Inventories Adjustments
- - - -

Silverback Therapeutics Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Inventories, Inventories Adjustments Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Silverback Therapeutics Inventories, Inventories Adjustments Calculation

Inventories, Inventories Adjustments represents certain charges made in the current period in inventory resulting from breakage, spoilage, employee theft and shoplifting, etc.


Silverback Therapeutics (Silverback Therapeutics) Business Description

Industry
Traded in Other Exchanges
N/A
Address
500 Fairview Avenue N, Suite 600, Seattle, WA, USA, 98109
Silverback Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on leveraging its ImmunoTAC technology platform to develop tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases.
Executives
Brian Dorsey officer: Chief Operating Officer C/O SOMAXON PHARMACEUTICALS, INC., 10935 VISTA SORRENTO PARKWAY, SUITE 250, SAN DIEGO CA 92130
Alexander A Fitzpatrick officer: Chief Legal Officer 9605 SCRANTON ROAD, SUITE 200, SAN DIEGO CA 92121
Brent L Saunders director 2000 GALLOPING HILL ROAD, C/O SCHERING PLOUGH CORP, KENILWORTH NJ 07033
Pratik Shah Living Trust Dated June 15, 2011 10 percent owner C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Michael Kelly director C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Rajeev Dadoo director C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Sarina Tanimoto 10 percent owner, officer: Chief Medical Officer C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Eric Karas officer: Chief Commercial Officer C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Justin Chakma officer: Chief Business Officer C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Richard E Lowenthal director, 10 percent owner, officer: President and CEO 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Pratik Shah director, 10 percent owner 3366 N. TORREY PINES COURT, SUITE 220, LA JOLLA CA 92037
Ra Capital Nexus Fund Ii, L.p. director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Kathleen D. Scott officer: Chief Financial Officer C/O CONATUS PHARMACEUTICALS INC., 16745 WEST BERNARDO DRIVE, SUITE 200, SAN DIEGO CA 92127
Deerfield Mgmt Iv, L.p. director, 10 percent owner, other: * Director by deputization 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Private Design Fund Iv, L.p. director, 10 percent owner, other: * Director by deputization 780 THIRD AVENUE 37TH FLOOR, NEW YORK NY 10017

Silverback Therapeutics (Silverback Therapeutics) Headlines

From GuruFocus

Silverback Therapeutics and ARS Pharmaceuticals Announce Merger

By Business Wire Business Wire 07-21-2022